{"filing":{"accession_number":"0001104659-26-086674","cik":"0001971387","ticker":"LIMNW","company_name":"Liminatus Pharma, Inc.","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-20","primary_document":"tm2621298d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926086674/tm2621298d1_8k.htm"},"events":[{"id":20511,"run_id":18457,"accession_number":"0001104659-26-086674","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Liminatus Pharma failed to regain compliance with Nasdaq's minimum bid price rule ($1 per share) and is ineligible for a second 180-day extension. The Nasdaq Hearings Panel will decide on continued listing, with no assurance the company can regain compliance.","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19885,"accession_number":"0001104659-26-086674","item_number":"3.01","item_title":"Notice of Delisting or Failure to","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"The filing discloses that Liminatus Pharma failed to regain compliance with Nasdaq's minimum bid price rule ($1 per share) and is ineligible for a second 180-day extension. The Nasdaq Hearings Panel will decide on continued listing, with no assurance the company can regain compliance. This is a direct delisting risk disclosure under Item 3.01, materially threatening the company's exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:52:38.458416+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":20512,"run_id":18457,"accession_number":"0001104659-26-086674","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.65,"summary":"A definitive proxy statement was filed on July 13, 2026 for an annual stockholder meeting scheduled for August 3, 2026, with the primary purpose of authorizing a reverse stock split to address Nasdaq minimum bid price compliance concerns.","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19886,"accession_number":"0001104659-26-086674","item_number":"8.01","item_title":"Other Events.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.65,"reasoning":"The filing discloses that a definitive proxy statement was filed on July 13, 2026 for an annual stockholder meeting scheduled for August 3, 2026, with the primary purpose of authorizing a reverse stock split. While this is technically a pre-vote disclosure rather than vote results, the forward-looking statements reference Nasdaq compliance concerns, suggesting the reverse split is a material governance action to address listing standards. The disclosure is material to investors as it signals potential delisting risk and a significant corporate action.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:52:38.458416+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19885,"accession_number":"0001104659-26-086674","item_number":"3.01","item_title":"Notice of Delisting or Failure to","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"The filing discloses that Liminatus Pharma failed to regain compliance with Nasdaq's minimum bid price rule ($1 per share) and is ineligible for a second 180-day extension. The Nasdaq Hearings Panel will decide on continued listing, with no assurance the company can regain compliance. This is a direct delisting risk disclosure under Item 3.01, materially threatening the company's exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:52:38.458416+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-07-24"},{"id":19886,"accession_number":"0001104659-26-086674","item_number":"8.01","item_title":"Other Events.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.65,"reasoning":"The filing discloses that a definitive proxy statement was filed on July 13, 2026 for an annual stockholder meeting scheduled for August 3, 2026, with the primary purpose of authorizing a reverse stock split. While this is technically a pre-vote disclosure rather than vote results, the forward-looking statements reference Nasdaq compliance concerns, suggesting the reverse split is a material governance action to address listing standards. The disclosure is material to investors as it signals potential delisting risk and a significant corporate action.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:52:38.458416+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-07-24"}]}